Across 844,108 adults in China, the UK, the USA and Spain, adding waist circumference and waist-to-height ratio to BMI reclassified obesity status: BMI alone missed 5.2-8.6% of people with obesity and wrongly flagged 1.2-3.1%. Clinical obesity, defined by adiposity-related organ dysfunction, made up 22.7-31.3% of all obesity and carried a hazard ratio of 1.69 for all-cause mortality. Preclinical obesity, with preserved organ function, showed only 1.19, and 77.4-91.3% of those individuals had not progressed to clinical disease after 10 years.
The practical message for adults is that BMI is a weak gatekeeper in both directions. Someone with a normal BMI but a large waist may carry real risk that a routine check misses, so waist measurement deserves a place beside the scale. The preclinical finding matters just as much: excess fat without organ dysfunction is not a death sentence, and most such cases stayed stable, which argues for monitoring and lifestyle intervention over reflexive escalation. Limitations are real. Observational data cannot show that treating preclinical obesity changes outcomes, and organ dysfunction is itself a downstream consequence that may partly explain the mortality gap, making the clinical category somewhat circular. Ethnic differences in fat distribution also complicate universal cutoffs. Editorially, this is a strong confirmatory validation rather than a paradigm shift, but its multi-country scale gives the Lancet Commission framework the empirical footing it previously lacked.